Individuals with deleterious germline mutations in the tumor suppressor gene BRCA1 are at an increased risk for breast and ovarian cancers that are associated with poor disease outcomes. While cancer screenings have helped identify BRCA1 variants in patients, there is not enough information on many of these variants to determine if they are deleterious and thus link them with disease predisposition. To infer the cancer risk of these variants of uncertain significance (VUS), many functional assays have been developed to characterize variant BRCA1 protein functions. In this review, we will discuss the assays that have been used to examine the function of variant BRCA1 proteins and how functional assays are increasing throughput from methods that test one variant at a time to multiplexed formats. Multiplex assays utilizing homology-directed repair (HDR) and saturation genome editing (SGE), among others, have been able to evaluate more thoroughly BRCA1 variants and functional regions. Based on these new developments in BRCA1 functional assays, we will also discuss the need for more multiplexed assays to increase confidence in functional interpretation and other potential approaches for better classifying BRCA1 VUS.
1 Introduction: Hereditary breast and ovarian cancers (HBOCs) are caused by germline mutations in tumor suppressor genes, and account for 5-10% of breast cancer cases 1 and 23% of ovarian cancer cases 2 . A plurality of HBOCs are caused by mutations in BRCA1 and BRCA2, which account for 25% of hereditary breast cancers 3 and 12% of hereditary ovarian cancers 4 . HBOCs also result in a greater increased cancer risk than what is observed in the general population. While a minority of individuals with breast and ovarian cancers have hereditary disease, individuals with pathogenic BRCA1 variants have a 65% lifetime risk for breast cancer and a 39% risk for ovarian cancer 5 , as compared to the 12.4% breast cancer risk and 1.3% ovarian cancer risk present in the general population according to the National Cancer Institute. Individuals with pathogenic BRCA1 variants also often develop triple negative breast cancers, which have low survival rates 6 .
The BRCA1 protein has many functions associated with tumor suppression. BRCA1 encodes a 1863 amino acid protein that features an amino-terminal RING domain, a DNA binding domain (DBD), coiled coil (CC) domain, and two tandem carboxyterminal BRCT domains 7 . The BRCA1 protein forms an obligate heterodimer with another tumor suppressor protein, BARD1, via their RING 8 and BRCT 9,10 domains. This interaction mediates tumor suppressor activity through direct mediation of DNA repair via the recruitment of RAD51 to sites of DNA double-strand breaks [11] [12] [13] . The BRCA1 BRCT domains also bind to several phosphoproteins 14, 15 . Binding to Abraxas mediates BRCA1 recruitment to sites of DNA damage 16 , BRIP1 is a DNA helicase involved in DNA repair 17, 18 and CtIP mediates DNA end resection following DNA damage 19 . BRCA1 has also been shown to activate transcription via its C-terminus 20 , mediate checkpoint activation 21 , and ubiquitinate γ-tubulin to regulate the centrosome number in the cell 22 .
Thanks to the increased accessibility and affordability of clinical sequencing and cancer screening, a large number of BRCA1 missense variants have been identified. However, the sequencing data are insufficient to differentiate neutral and pathogenic variants, and many variants do not occur frequently enough in the population to assign a clinical risk. These are known as variants of unknown clinical significance (VUS). According to the ClinVar database 23 , which records the clinical significance of gene variants, about 50% of known BRCA1 variants are considered VUS or have conflicting reports of pathogenicity. VUS in BRCA1 and BRCA2 are found in 10-20% of cancer screenings 24 , indicating that individuals are often informed of their uncertain cancer risk. Individuals with BRCA1 variants are often heterozygous for wild-type BRCA1 and are at risk for loss of heterozygosity (LOH), where expression of the wild-type allele is lost and cells become homozygous for the BRCA1 variant, which may increase cancer risk 25 . There exist preventative measures for breast and ovarian cancers such as mastectomy and salpingooophorectomy, but these are invasive procedures that should only be done if necessary 26 . Based on the potential severity of the disease and the exponentially higher risk associated with HBOCs, there is an essential and pressing need to identify which germline variants are associated with disease. Functional assays may help categorize this large number of BRCA1 VUS by correlating protein function with cancer predisposition.
BRCA1 Functional Assays
While frame-shift or nonsense variants are likely to cause loss of protein function, it is much more difficult to predict the effect of missense variants that change a single amino acid. Numerous assays have been developed to examine BRCA1 function, although their sensitivity and specificity can vary. Many involve DNA repair. The homology-directed repair (HDR) assay examines the ability of variants to mediate homologous recombination [27] [28] [29] . The HDR assay uses a reporter cell line containing two non-functional GFP coding sequences, one of which is interrupted by a cut site for the rare-cutting restriction endonuclease ISceI. If BRCA1 variants are functional in HDR, the other GFP allele will be used as a template to repair a double-strand break induced by I-SceI, resulting in functional GFP expression that can be quantified 27, 29 . The HDR assay has also been used to examine the function of BARD1 variants, as BRCA1 and BARD1 are found in an obligate heterodimer and both are necessary for mediating DNA repair 9,30 . BRCA1 variants have also been tested in a similar assay for single-strand annealing (SSA), where a double-strand break in a GFP allele is induced in a reporter HeLa-SSA cell line 31 . DNA resecting reveals homology with an upstream GFP allele, resulting in repair and green fluorescence. Nearly 150 BRCA1 variants have been examined using the HDR assay, and with the exception of splicing variants the assay has shown 100% specificity and sensitivity (Figure 1 ). Results were combined from four papers that examined BRCA1 variants in HDR 27,28,31,32 and variants were color-coded by functional domain. HDR activity, as quantified by percent GFP-positive cells, was normalized to the activity of cells complemented with wild-type BRCA1, which was set to one (lane 1). Cotransfection of a plasmid expressing wildtype BRCA1 fully rescued loss of endogenous BRCA1 expression. Cells depleted of BRCA1 (lane 2) showed a 10-fold drop in DNA repair activity. Known benign variants were labeled with blue dots, known pathogenic variants were labeled with red dots, and VUS were labeled with gray dots. In one of these studies 28 , germline and tumor samples were evaluated for LOH, and 17 codons in BRCA1 were found to have significantly elevated LOH in the tumor. Of these only 6 were nonfunctional in the HDR assay, suggesting that LOH does not accurately predict loss of function variants. Non-functional missense variants were located in the RING and BRCT domains, consistent with the locations of known pathogenic variants and suggesting that future analysis could focus on the N-and C-termini. [65] [66] [67] [68] . Programs like VarScan, Pindel and GATK can also be used to identify potentially pathogenic variants from sequencing data [69] [70] [71] . Ideally, the information gained from functional assays of BRCA1 can also be extended to similar proteins. Functional analysis from BRCA1 BRCT domain variants tested in the transcription activation assay has been used to update the VarCall model and identify potentially pathogenic variants in other proteins containing BRCT domains 72 . While in silico and bioinformatics analysis can help evaluate a large number of variants, the conclusions are not always accurate and there is not enough preexisting, validated data in these programs. Such programs are best used in conjunction with functional assays to characterize variants and provide more empirical evidence to improve program output.
Multiplexed Assays
While these functional assays are very useful for identifying BRCA1 variants, they are limited by the fact that only a single variant can be expressed in a tested cell population and therefore each needs to be tested one at a time. With each additional variant tested, more time and resources are needed. To accurately examine the function of a protein like BRCA1, all potential variants in a region of interest or even the whole gene need to be examined. That would require testing hundreds or thousands of variants, which is not feasible for the experimental procedures discussed earlier. Multiplexed approaches allow for a greater number of variants to be tested by expressing hundreds to thousands of variants in the same cell population.
Multiplex assays require experimental procedures that allow for the examination of large numbers of variants. Multiplex CRISPR/Cas9 knockout screens have been used to identify essential genes in various cancer cell lines to better target cancer treatments 73 . A large number of assays utilize deep mutational scanning, where every possible amino acid change at every protein position is generated and functional effects are examined 74 . Several methods have been developed for generating hundreds or thousands of mutations. Variants can be introduced at random by controlling the PCR mutagenic rate 75 . Variants can also be generated through targeted methods such as programmed allelic series (PALS) mutagenesis, where mutagenic primers to the region of interest are synthesized on a microarray and a degradable wild-type template introduces Copyright 78 . SNVs can also be generated using saturation editing by inserting a library of all potential DNA hexamers into a region of interest and inserting the mutagenized region into the genome with CRISPR/Cas9 RNA-guided cleavage 79 . It is useful to examine SNVs because they account for the majority of human mutations 80 , but SNV studies do not provide the same structure-function information available with studies that examine all possible amino acid changes. Functional variants are identified via highthroughput DNA sequencing to examine which variants are depleted by comparing the variant distribution in the input sample versus the experimental sample, and the frequency of a given variant in each pool is used to determine function 74, 81 .
A variety of protein and gene functions have been examined using multiplex assays. Enhancer activity has been extensively studied via deep mutational sequencing multiplex reporter assays 82, 83 . All possible SNVs of the liver enhancers ALDOB, ECR11 and LTV1 were generated to examine changes in enhancer function 84 . Thousands of candidate liver enhancers have also been examined for function via lentivirus-based multiplex reporter assays 85 
Multiplexed Assays for Analyzing the Function of BRCA1 Missense Variants
BRCA1 has been extensively examined via deep functional sequencing using several different functional assays (Figure 2) . Variants in the first 300 amino acids of BRCA1, including those in the RING domain, have been examined for their E3 ubiquitin ligase activity and BARD1 binding activity 32 . Variants were expressed on the surface of T7 bacteriophage and those that autoubiquinated 93 in the presence of ubiquitin were selected. Binding between the BRCA1 and BARD1 RING domains was examined using multiplexed yeast twohybrid assays. Examination of E3 ligase activity showed that the zinc ion residues that maintained RING domain structure and residues that interact with E2 ubiquitin enzyme UbcH5c 97 were most frequently non-functional due to mutations. Results were similar with regards to BARD1 binding -variants that affected the zinc ions, and subsequently RING domain structure, were most intolerant to substitution.
HDR has been directly assessed to examine the function of missense variants in the BRCA1 N-terminus 98 . Missense variants in the first 192 amino acids of BRCA1 were generated and subjected to the HDR assayvariants were sorted into GFP-positive and GFP-negative pools, and then the barcodes attached to each variant were sequenced. All of the non-functional variants identified were nonsense variants or were located in the RING domain, which has extensively studied repair functions. Known benign variants were functional in HDR, while all known pathogenic variants, except for the splicing variant R71G 99 , were nonfunctional, resulting in 87.5% sensitivity and 100% specificity for the assay. Examining the relationship between HDR function and protein structure also Multiplex analysis of BRCA1 function has also been measured via the growth of human haploid HAP1 cells, where BRCA1 and other HDR-related genes are necessary for cell survival 100 . Instead of generating all potential amino acid variants, the authors examined the function of all potential SNVs. Saturation genome editing (SGE) of the BRCA1 gene in situ was used to generate all possible variants in the 13 exons that make up the RING and BRCT domains 79 . SNVs that inhibited BRCA1 function were selected against by increasing HDR rates in HAP1 cells, and the gDNA and RNA of variants present in the input population was sequenced and compared to the variants present in the population after multiple passages. Using SGE to generate all potential SNVs allowed the authors to examine splicing 79 , finding that SNVs that disrupted splice sites were non-functional and had depleted mRNA. Most nonfunctional missense SNVs also did not have reduced RNA levels, indicating that loss of function was mostly due to protein defects. As previously seen in the multiplex assays on E3 ubiquitin ligase function and HDR, variants that affected RING domain folding, which affects binding to BARD1, and buried hydrophobic residues were nonfunctional.
When the results of all four multiplexed assays for BRCA1 function were compared, nearly all of the results were consistent 98 . The multiplexed HDR and SGE assays had results that were consistent for over 100 variants. The L22S missense variant was found to be functional in the ubiquitin ligase and BARD1 binding assays 32 but was non-functional in HDR, and only five variants had discrepant results when comparing the HDR and SGE assays.
The Future of Examining BRCA1 Variant Function
Assays examining many BRCA1 functions, such as HDR, transcription activity and nuclear localization, have been used to characterize BRCA1 variants and infer pathogenicity. In recent years, new developments in multiplexed approaches have been applied to study BRCA1 variants as well, to characterize BRCA1 functional domains more broadly and comprehensively.
Multiplexed assays examining ubiquitin ligase activity, BARD1 binding activity, HDR, and cell fitness examine the BRCA1 N-and C-termini, and have had a general consensus of functional results.
With the existence of multiple functional assays for BRCA1 and multiplexing making it more feasible to characterize thousands of variants at once, this begs the question of what is the "best" assay to use for identifying pathogenic variants. BRCA1 has been shown to be involved in functions such as DNA repair, centrosome regulation and transcription, so which of these functions is the best for predicting clinical risk? It appears that no one assay is perfect, and they all serve different purposes because function is context-specific. Testing the same variants in the HDR and SSA DNA repair processes has shown that all known pathogenic variants were defective in both processes 31 . However, the SSA assay also identified several benign Copyright 55 . Another factor that many functional assays do not address is splicing variants, as many of the assays discussed utilize cDNA and do not account for them. The variety of responses regarding BRCA1 function that are provided by these assays show that there is no one true functional assay, and that multiple assays are needed to fully characterize a gene like BRCA1.
Ultimately, the functional assays should augment genetic information to enable a clinician to advise individuals about their risk for breast and ovarian cancer. As more functional assays are conducted, more confidence can be placed on their predictive value. All four published multiplexed BRCA1 assays had results that were overall consistent with each other. We suggest that the confidence in the predictive value is higher for the variants that have common results, as indicated by the more than 100 variants whose function was consistent between the HDR and SGE assays 98 . When results differ, it could be due to technical error, or possibly due to real differences in the amino acid requirements of the two assays. The multiplexing of additional BRCA1 functional assays, as well as the application of already-validated multiplex assays to other domains of BRCA1, would allow for better understanding of BRCA1 and improved classification of BRCA1 variants. Copyright 
